A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ-54861911 which is currently being developed for the treatment of Alzheimer's Disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a first-in-human, double-blind (neither investigator nor participant knows which treatment the participant receives), randomized (participants are assigned different treatments based on chance), placebo-controlled (placebo is an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial), single-ascending dose study. The study is designed to evaluate the safety (side effects), tolerability and pharmacokinetics (how the drug is absorbed in the body, distributed within the body, and how it is removed from the body over time, ie, what the body does to the drug), and pharmacodynamics (what the drug does to the body) of JNJ-54861911 which is currently being developed for the treatment of Alzheimer's Disease.

The study population will consist of approximately 64 healthy participants divided among approximately 8 cohorts (small groups). Each cohort will have 8 participants.

For all participants the study will consist of 3 phases: a screening phase (between 28 and 2 days prior to the first dose administration), a double-blind treatment phase, and a follow-up examination (within 7 to 14 days after last dose administration). Participants who successfully complete the screening examination and are considered eligible to participate will be admitted to the clinical unit on Day -1 before administration of the study drug and will remain in the unit until the evening of Day 3.

The double-blind treatment phase will consist of three parts: Part 1 (Cohorts 1 to 3) is a single ascending dose part in young healthy male participants, between 18 and 54 years of age. Part 2 (Cohorts 4 to 7) is a single-ascending dose part in elderly male and female participants between 55 and 75 years of age including continuous cerebrospinal fluid (CSF) sampling. Within Parts 1 and 2 of the study, participants will be randomized (assigned by chance) to treatment with JNJ-54861911 (n=6/cohort) or matching placebo (n=2/cohort). Following each dose level, the observed safety and tolerability profile will be evaluated. If no side effects are observed and the pharmacokinetic data are roughly in line with predicted safe values, the dose will be escalated. Each participant of the next cohort will be given a higher dose of JNJ-54861911. As a general safety precaution for a first-in-human study, all dose administrations in Part 1, Cohort 1 and all further cohorts will be staggered.

Part 1 of the study will primarily focus on determining safety and tolerability of JNJ-54861911 after single ascending dose administrations and understanding the primary pharmacokinetic characteristics of JNJ-54861911. In addition possible pharmacodynamic effects of JNJ-54861911 on plasma amyloid beta (Aβ) levels will be explored. The primary focus of Part 2 will be determining the maximal tolerated dose level of JNJ-54861911 or determine the safety and tolerability at the maximum feasible exposure level, whichever is reached first in healthy elderly participants. In addition the reduction in CSF Aβ over 36 hours post single dose administration of JNJ-54861911 will be explored. Planned doses will be 1 mg, 3 mg, 9 mg, 27 mg, 81 mg, and 160 mg of JNJ- 54861911 or matching placebo, administered as a single oral dose. The starting dose of JNJ-54861911 in Part 2 will be the dose level tested in Part 1 found to be safe and well tolerated, and that is expected to reduce CSF Aβ by 20 percent or more. The initial dose tested in Part 2 will not be higher than the doses tested in Part 1.

Part 3 (Cohort 8) of the study will evaluate the effect of food on how JNJ-54861911 is absorbed, distributed within the body, and removed from the body. One single dose of JNJ-54861911 or matching placebo will be tested after consumption of a high fat breakfast. The dose of JNJ-54861911 tested in this part will be derived from the results obtained in Parts 1 and 2. Part 3 may be performed in parallel with Part 1 or 2 of the study. Depending on the pharmacokinetic properties and safety and tolerability profile of JNJ-54861911, young or elderly healthy participants may be recruited for this part. In addition male participants enrolled in Part 1 or Part 2 may also be enrolled for Part 3.

Participants will be discharged from the clinical unit after the last study assessment on Day 3 has been obtained. Participants will only be discharged if in the opinion of the investigator it is safe for the participants to be discharged. The participant will return to the clinical unit on Day 4 (72 h post dose) and Day 5 (96 h post dose) for plasma PK sampling. Safety assessments will be performed throughout the study. The maximal study duration for a participant will not exceed 6 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1 - Cohort 1: JNJ-54861911 1 mg

Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.

Participants in each cohort will receive matching placebo.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo will be given as a single oral dose.

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Good general health
* Must adhere to required contraception during and for 3 months after study

* Body mass index between 18 and 30 kg/m2
* Male volunteers, between 18 and 54 years of age, inclusive

* Body mass index between 18 and 32 kg/m2
* Women must be postmenopausal, permanently sterilized or otherwise be incapable of pregnancy
* Healthy male or female volunteers, between 55 and 75 years of age, inclusive

* Male volunteers

Exclusion Criteria

* Clinically significant medical or psychiatric illness
* Alcohol or substance abuse; excessive nicotine or caffeine use
* Recently received an investigational drug, vaccine, or invasive medical device
* Unable to abide by protocol restrictions on use of other medications
* History or family history of spontaneous, prolonged or severe bleeding of unclear origin or of blood clotting
* Current anemia

* History of lower back pain or scoliosis and/or major (lumbar) back surgery
* Allergic to local anesthetics and/or iodine
* Increased intracranial pressure based on fundoscopy

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Antwerp, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-000215-24

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR101083

Identifier Type: -

Identifier Source: org_study_id

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Study Groups

Part 1 - Cohort 1: JNJ-54861911 1 mg

JNJ-54861911 1mg

Part 1 - Cohort 2: JNJ-54861911 3 mg

JNJ-54861911 3 mg

Part 1 - Cohort 3: JNJ-54861911 9 mg

JNJ-54861911 9 mg

Part 2 - Cohort 4: JNJ-54861911 9 mg

JNJ-54861911 9 mg

Part 2 - Cohort 5: JNJ-54861911 27 mg

JNJ-54861911 27 mg

Part 2 - Cohort 6: JNJ-54861911 81 mg

JNJ-54861911 81 mg

Part 2 - Cohort 7: JNJ-54861911 160 mg

JNJ-54861911 160 mg

Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])

JNJ-54861911 tbd

Parts 1 through 3 - Placebo

Placebo

Interventions

JNJ-54861911 1mg

JNJ-54861911 3 mg

JNJ-54861911 9 mg

JNJ-54861911 27 mg

JNJ-54861911 81 mg

JNJ-54861911 160 mg

JNJ-54861911 tbd

JNJ-54861911 9 mg

Placebo

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Janssen Research & Development, LLC

Responsible Party

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Locations

Countries

Other Identifiers

2013-000215-24

CR101083